問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Rheumatology

Division of Dermatology

Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

更新時間：2023-09-19

洪維廷
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

33Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

洪維廷

Taichung Veterans General Hospital

Division of Rheumatology

List

31Cases

2023-10-15 - 2025-06-18

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2021-10-01 - 2028-07-07

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-06-01 - 2026-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting3Sites

Recruiting7Sites

2019-07-04 - 2022-05-31

Phase II

Completed
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    Elsubrutinib, Upadacitinib

Participate Sites
6Sites

Recruiting6Sites

2023-06-01 - 2026-06-08

Phase III

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-Severe Symptom State

  • Condition/Disease

    Sjögren’s Syndrome

  • Test Drug

    injection

Participate Sites
4Sites

Recruiting4Sites

2026-06-01 - 2029-01-16

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2024-11-01 - 2029-12-11

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2025-11-15 - 2030-03-31

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2025-10-28 - 2027-04-16

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-12-02 - 2030-12-09

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB